| Carl Puzant Garabedian, MD | |
|
101 W 8th Ave, Suite 4300, Spokane, WA 99204-2307 | |
| (509) 747-6707 | |
| (509) 624-9186 |
| Full Name | Carl Puzant Garabedian |
|---|---|
| Gender | Male |
| Speciality | Pediatric Medicine |
| Experience | 29 Years |
| Location | 101 W 8th Ave, Spokane, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083666127 | NPI | - | NPPES |
| 000568 | Medicaid | OR | |
| 806205300 | Medicaid | ID | |
| 8280570 | Medicaid | WA | |
| 0149942 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0202X | Pediatrics - Pediatric Cardiology | MD00039312 (Washington) | Primary |
| 2080P0202X | Pediatrics - Pediatric Cardiology | M-8823 (Idaho) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prov Sacred Hrt Med Ctr & Childs Hosp. | Spokane, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Washington | 0345139929 | 687 |
| Providence Health And Services Washington | 0345139929 | 687 |
News Archive
There is no treatment yet for dementia; but one day, a family doctor could prescribe a specific diet, an exercise regime, music or language lessons, or documentary discussion groups as treatments to ward off the disease.
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,659,096 with claims that cover the use of amplification consumables in several current real-time and end point PCR instruments.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
Nearly half of all Americans will outlive their assets, dying with practically no money at all. Even more worrisome, that's true even among households that met the traditional standards for secure retirement income. ... The results can be measured in more than merely dollars and cents. [MIT Economist James] Poterba's paper found that this group is "disproportionately in poor health," in part because they have no resources to cover medical expenses outside Medicare. Most shocking, many of these households were considered to have entered retirement in good financial shape; they didn't count on outliving their plans (Michael Hiltzik, 7/16).
› Verified 4 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194099390 PECOS PAC ID: 0345139929 Enrollment ID: O20040311001453 |
News Archive
There is no treatment yet for dementia; but one day, a family doctor could prescribe a specific diet, an exercise regime, music or language lessons, or documentary discussion groups as treatments to ward off the disease.
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,659,096 with claims that cover the use of amplification consumables in several current real-time and end point PCR instruments.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
Nearly half of all Americans will outlive their assets, dying with practically no money at all. Even more worrisome, that's true even among households that met the traditional standards for secure retirement income. ... The results can be measured in more than merely dollars and cents. [MIT Economist James] Poterba's paper found that this group is "disproportionately in poor health," in part because they have no resources to cover medical expenses outside Medicare. Most shocking, many of these households were considered to have entered retirement in good financial shape; they didn't count on outliving their plans (Michael Hiltzik, 7/16).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carl Puzant Garabedian, MD Po Box 421, Liberty Lake, WA 99019-0421 Ph: (509) 747-6707 | Carl Puzant Garabedian, MD 101 W 8th Ave, Suite 4300, Spokane, WA 99204-2307 Ph: (509) 747-6707 |
News Archive
There is no treatment yet for dementia; but one day, a family doctor could prescribe a specific diet, an exercise regime, music or language lessons, or documentary discussion groups as treatments to ward off the disease.
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,659,096 with claims that cover the use of amplification consumables in several current real-time and end point PCR instruments.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
Nearly half of all Americans will outlive their assets, dying with practically no money at all. Even more worrisome, that's true even among households that met the traditional standards for secure retirement income. ... The results can be measured in more than merely dollars and cents. [MIT Economist James] Poterba's paper found that this group is "disproportionately in poor health," in part because they have no resources to cover medical expenses outside Medicare. Most shocking, many of these households were considered to have entered retirement in good financial shape; they didn't count on outliving their plans (Michael Hiltzik, 7/16).
› Verified 4 days ago
Robert E Piston, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6002 N Lidgerwood St, Spokane, WA 99208 Phone: 509-482-4402 Fax: 509-483-7631 | |
Dr. Tanisha Kamille Morton, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 6002 N Lidgerwood St, Spokane, WA 99208 Phone: 509-482-4402 | |
Sarah E D'hulst, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 400 E 5th Ave, Spokane, WA 99202 Phone: 509-838-2531 | |
Dr. Joseph Paul Kincaid, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 408 W 25th Ave, Spokane, WA 99203 Phone: 509-999-8237 | |
Carrie Elizabeth Laborde, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 101 W 8th Ave Fl 3, Spokane, WA 99204 Phone: 509-474-2777 Fax: 509-474-6222 | |
Dr. David Ross Goshorn, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 101 W 8th Ave, Pshmc 3rd Flr, Spokane, WA 99204 Phone: 509-474-2277 | |
Dr. Ronda Jean Gretebeck, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 35 W 8th Ave, Spokane, WA 99204 Phone: 509-456-6556 Fax: 509-455-8801 |